Newsroom

Press releases & News

Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results

LAV321demonstrated strong results in its third consecutive year of field trials in Europe   REHOVOT, ISRAEL – November 19, 2024 – Lavie Bio Ltd., a leading ag-biologicals company and subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced significant progress in the development of its LAV321 bio-fungicide, targeting downy mildew.  Over three years of

Read more

Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials

Lavie Bio intends to commence Yalos® sales for soybean in 2025 US spring season     Rehovot, Israel – November 12th, 2024 – Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced the commercial expansion of Yalos® seed-treatment to soybean, following successful field trials performed in 2024

Read more

Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of ‘MicroFermentor’, a Unique Technology that Can Change the Economics of Ag-Biologicals

The technology aims to reduce application costs, extend shelf life, and prolong bacterial viability after field application REHOVOT, ISRAEL – September 30th, 2024 – Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), announced receiving a grant from the Israel Innovation Authority (IIA) to advance its program

Read more

Lavie Bio Announces Commercial Expansion of Yalos™ to Winter Wheat

Lavie Bio successfully completed testing of Yalos™ for winter wheat and will commence sales across the US for the 2024-2025 season   Rehovot, Israel – July 2nd, 2024 – Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), is pleased to announce the commercial expansion of its

Read more

Bayer AG and Lavie Bio Continue for Second Year of Biofungicides Validation Following Successful Lab and Greenhouse Testing

Rehovot, Israel – March 19, 2024 —Lavie Bio Ltd., a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), announced today that it is extending its joint validation trials for its biofungicides conducted by Bayer AG, a global leader in the agriculture

Read more

Lavie Bio and Ceres Global Ag Corp. Collaborate to Include YalosTM Bio-Inoculant, in Regenerative Agriculture Initiatives in North America

Rehovot, Israel – March 13, 2024 — Lavie Bio Ltd., a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced that Ceres Global Ag Corp. (“Ceres”) a global agricultural, energy and industrial products merchandising and supply chain company, has chosen

Read more

Lavie Bio Successfully Secures Second Half Advance Payment of $2.5M after Meeting Corteva’s Licensing Agreement Requirements

The payment completes the $5M advance payment received under the licensing agreement for bio-fungicide product candidates   REHOVOT, ISRAEL – February 28, 2024 – Lavie Bio Ltd., a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products, and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), announced that it has successfully

Read more

Lavie Bio Announces a Distribution Agreement with WinField United Canada for its Bio-Inoculant Seed Treatment YalosTM

  The agreement supports Lavie Bio’s 2024 sales growth plan for spring wheat, durum, and barley in Canada   Rehovot, Israel – December 5, 2023 — Lavie Bio Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products, today announced a distribution

Read more

Lavie Bio Reports Advancement in Bio-Fungicide Program Against Downy Mildew with 2023 Field Trial Results

LAV321, discovered and optimized by Lavie Bio, delivered positive results in 2023 field trials across Europe and the US, protecting against downy mildew REHOVOT, ISRAEL – November 8, 2023 – Lavie Bio Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), and a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel

Read more

Lavie Bio Announces Licensing Agreement for Bio-Fungicides with Corteva Agriscience

Corteva to receive exclusive rights to further develop and commercialize Lavie Bio’s lead product candidates for fruit rot and powdery mildew fungicide biologicals   REHOVOT, ISRAEL – JULY 17, 2023 – Lavie Bio Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), and a leading ag-biologicals company that develops microbiome-based, computational driven bio-stimulant and

Read more

Lavie Bio Receives Canadian Regulatory Approval for ThrivusTM, Expanding Global Reach

The approval by the Canadian Food Inspection Agency triples Thrivus’TM sales territory Rehovot, Israel — May 24, 2023 — Lavie Bio Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), and a leading ag-biological company focusing on improving food quality, sustainability, and agricultural productivity through the introduction of microbiome-based products, today announced it had

Read more

Lavie Bio to Host a Round Table Discussion and is a Sponsor at World Agri-Tech Conference in San Francisco

Rehovot, Israel – March 6, 2023 — Lavie Bio Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), and a leading ag-biological company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, today announced in that its management will be sponsoring and participating at the World Agri-Tech Conference

Read more

Lavie Bio Reports Successful Results for its Bio-Fungicides Programs

Positive results for LAV311 and LAV321 achieved in 2022 in a series of field trials, testing for protection against bunch rot, powdery mildew and blight diseases   Rehovot, Israel – February 28, 2023 — Lavie Bio Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), and a leading ag-biological company focusing on improving food

Read more

Lavie Bio Advances its Novel Bio-fungicide Program and Applies to the U.S. EPA for Regulatory Approval

LAV.311 is targeting fruit rots and powdery mildews fungal diseases Rehovot, Israel – October 12, 2022 — Lavie Bio Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), and a leading ag-biological company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, today announced submitting the registration package

Read more

Lavie Bio Announces Appointment of Guri Oron as CEO

Rehovot, Israel – September 14, 2022 — Lavie Bio Ltd. (“Lavie Bio”), a subsidiary of Evogene Ltd. (“Evogene”) (Nasdaq: EVGN, TASE: EVGN), and a leading ag-biologicals company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, today announced the appointment of Guri Oron as Chief Executive Officer (“CEO”) of

Read more

Lavie Bio Announces Successful Product Launch of its Bio-Inoculant result™ for the 2022 Spring Wheat Growing Season

Given wheat global shortages and high prices, Lavie foresees continued strong demand for its bio-inoculant result™ and plans increased production for 2023 growing season   Rehovot, Israel – May 11, 2022 — Lavie Bio Ltd., a subsidiary of Evogene Ltd., (NASDAQ: EVGN, TASE: EVGN) and a leading ag-biologicals company focusing on improving food quality, sustainability,

Read more

Lavie Bio Reports Advancement in its Bio-Fungicide Program for Fruit Rots

Advancement to the pre-commercial stage follows positive results from three consecutive years of vineyard trials for fruit rot diseases   Rehovot, Israel – December 14, 2021 – Lavie Bio Ltd., a leading ag-biologicals company focusing on improving food quality and agricultural productivity and sustainability through the introduction of microbiome-based products, and a subsidiary of Evogene

Read more

Lavie Bio Announces Commercial Launch of its First Microbiome-Based Product for Yield Improvement – result™

result™ inoculant initially introduced for spring wheat in North Dakota, following positive four-year field trials Rehovot, Israel – November 3, 2021 — Lavie Bio Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), and a leading ag-biologicals company focusing on improving food quality and agricultural productivity and sustainability through the introduction of microbiome-based products,

Read more

Lavie Bio and United Agronomy Announce Signing of Distribution Agreement for Lavie Bio’s Inoculant Product

Commercialization targeted for 2022 for spring wheat initially   Rehovot, Israel and Berthold, ND, USA – September 29, 2021 — Lavie Bio Ltd. (Lavie), a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), and a leading ag-biologicals company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, and United

Read more

Lavie Bio Announces the Appointment of Russ Putland as Vice President Commercial

This appointment continues Lavie Bio’s advancement of its commercial pipeline, focusing on its planned product launches starting 2022   Rehovot, Israel – May 25th, 2021 – Lavie Bio Ltd., a leading ag-biologicals company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd. (NASDAQ:

Read more

Lavie Bio Provides Product Pipeline Update for 2020

LAV211 bio-stimulant advancing towards anticipated 2022 commercial launch in spring wheat; Product advancement achieved in multiple programs   Rehovot, Israel – December 29, 2020 – Lavie Bio Ltd. (Lavie Bio), a leading ag-biologicals company focusing on improving food quality, sustainability and agriculture productivity through the introduction of microbiome-based products, and a subsidiary of Evogene Ltd.

Read more

Lavie Bio Announces the Appointment of Frederic C. Beudot, Global Portfolio Leader for Biologicals at Corteva Agriscience™, to its Board of Directors

Lavie Bio Announces the appointment of Frederic C. Beudot, Global Portfolio Leader for Biologicals at Corteva Agriscience™, as a member of  its Board of directors. With extensive experience in sales, marketing, commercial and strategy of crop protection product, Frederic will allow us to further strengthen our market and commercial focus as we progress toward product

Read more

Lavie Bio Announces Advancement in its Product Development Pipeline for Wheat Bio-Stimulants

Leading wheat bio-stimulant candidate for spring wheat, exhibiting consistent performance, advancing to ‘development stage 2’, in line with Lavie Bio’s commercialization plans for 2022 Rehovot, Israel – November 18, 2019 – Lavie Bio (Lavie), a subsidiary of Evogene (NASDAQ: EVGN, TASE: EVGN), aiming to improve food quality, sustainability and agriculture productivity through the introduction of

Read more

James Presnail has joined Lavie Bio as Chief Operating Officer.

In this position Jim will lead operational aspects and downstream development and commercialization efforts of Lavie Bio’s product pipeline as well as heading the Lavie Bio US site in St. Louis, Missouri.   Jim previously served as VP R&D and Director of Molecular Biology and Analytics at Calyxt. Prior to Calyxt, Jim was the Director

Read more

Lavie Bio, Evogene’s Ag-Biologicals Subsidiary, Announces the Nomination of Industry Experts to its Board of Directors

The nomination of industry experts is expected to support the company’s management in execution of its product development and commercialization roadmap  Rehovot, Israel – September 11, 2019 – Lavie Bio, a subsidiary of Evogene (NASDAQ, TASE: EVGN), focusing on improving food quality, agricultural sustainability and productivity through the development of novel microbiome based agriculture biological

Read more

In the press